Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED. SECRETARY OF THE SE

04 AUG -9 AM 11:

# **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Clark & Weinstock	
Registrant Address Check if different than Address 601 13th Street, N.W.  City Washington, State	previously reported Suite 410 South Zip (or Country) DC 20005
. Principal Place of Business (if different from line 2)	
City New York, State/	Zip (or Country) NY 10017
I. Contact Name Telep Lisa Hayes 202-	thone E-mail (optional) 5. Senate ID # 9443-595
7. Client Name  Self	6. House ID # 316-98054
O. Check if this is a Termination Report	] >> Termination Date 11. No Lob
O. Check if this is a Termination Report  INCOME OR EXPENSES - 0	44 32 2 1
O. Check if this is a Termination Report  INCOME OR EXPENSES - (  12. Lobbying Firms  INCOME relating to lobbying activities for	Complete Either Line 12 OR Line 13  11. No Lobi
O. Check if this is a Termination Report  INCOME OR EXPENSES - 0	Complete Either Line 12 OR Line 13  13. Organizations  14. No Lobe  15. This reporting EXPENSES relating to lobbying activities for this re-
D. Check if this is a Termination Report ☐  INCOME OR EXPENSES - 0  12. Lobbying Firms  INCOME relating to lobbying activities for period was:  Less than \$10,000 ☐  \$10,000 or more ☒ >>\$ \$180,000	Termination Date  11. No Lobic Complete Either Line 12 OR Line 13  13. Organizations  14. This reporting  EXPENSES relating to lobbying activities for this reperiod were:  Less than \$10,000   15. Organizations  EXPENSES relating to lobbying activities for this reperiod were:  Less than \$10,000   Expenses (nearest \$20,000)
O. Check if this is a Termination Report ☐  INCOME OR EXPENSES - O  12. Lobbying Firms  INCOME relating to lobbying activities for period was:  Less than \$10,000 ☐  \$10,000 or more ☒ >> \$ \$180,000 ☐  Income (n)  Provide a good faith estimate, rounded to the \$20,000 of all lobbying related income from	Termination Date  11. No Lobic Complete Either Line 12 OR Line 13  13. Organizations  EXPENSES relating to lobbying activities for this reperiod were:  Less than \$10,000   Expenses (nearest accounting method. See instructions for description on the client
0. Check if this is a Termination Report ☐  INCOME OR EXPENSES - 0  12. Lobbying Firms  INCOME relating to lobbying activities for period was:  Less than \$10,000 ☐  \$10,000 or more ☒ >> \$ \$ \$180,000 ☐  Income (n)	Termination Date  11. No Lob  Complete Either Line 12 OR Line 13  13. Organizations  EXPENSES relating to lobbying activities for this reperiod were:  Less than \$10,000   14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of the client any other entity  Method A. Reporting amounts using LDA defin

Signature			Date	UUVV
 Printed Name and Title	Vin Weber - Partner	r		I

Regis	strant Name:	Clark & Weinstock	
Clien	nt Name:	<u>PhRMA</u>	
enga	ged in lobbying		o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
15.	General issue	area code <u>HCR</u> (one per page)	
16.	Specific Lobb see attached	<del>-</del>	
17.	Department Executive O	Congress and Federal agencies contacted of Health & Human Services  Tice of the President presentatives	☐ Check if None
18.	Name of eacl	n individual who acted as a lobbyist in this is:	sue area
	Name		Covered Official Position (if applicable)
	Bieron, Bria	u <b>n</b>	
	Bonham, K	ent	
	Fazio, Vic		
	Glover Wei	ss, Juleanna	
	Godes, Niles	3	Chief of Staff to Sen. Byron Dorgan (D-ND)
	Kutler, Ed		
	Lehman, Di	rksen	Special Asst. for Leg. Affairs for the President
19.	Interest of ea	ch foreign entity in the specific issues listed	on line 16 above

Signature		<del></del>	Date	8/0/04		
Printed Name and Title	Vin Weber - Partner	 			<u></u> -	P

Clark & Weinstock Registrant Name: **PhRMA** Client Name: Data Description Item H.R. 2673, Agriculture, Rural Development, Food & Drug Administration and 16 **Lobbying Issues** Related Agencies Appropriations Act, 2004, sections related to FDA funding S. 51, Generic Pharmaceutical Access and Choice for Consumers Act of 2003; sections relating to substitution of generic drugs for innovator products. H.1, Medicare Prescription Drug and Modernization Act of 2003 & S. 1, Prescription Drug and Medicare Improvement Act of 2003, all sections relating new prescription drug benefits, drug access and reimportation. H.R. 2427, Pharmaceutical Market Access Act of 2003, relating to reimportation S. 1992 Defense of Medicare and Real Prescription Drug Benefit Act Medicare Enhancements for Needed Drugs Act of 2004 Implementation of Medicare law--P.L. 108-173; all sections related to prescripti drugs S. 2493, Safe Importation of Medical Products and Other Rx Therapies Act of S. 2307, Reliable Entry for Medicines at Everyday Discounts through Importa with Effective Safeguards Act of 2004 Mathews, Jim **Lobbyist Name** 18a **Covered Official Position** 18b No **New Lobbyist** 18c Morrison, Timothy **Lobbyist Name** 18a **Covered Official Position** 18b No **New Lobbyist** 18c Stach, Deirdre Lobbyist Name 18a 18b **Covered Official Position** No **New Lobbyist** 18c Stuart, Sandi 18a **Lobbyist Name Covered Official Position** 18b No **New Lobbyist** 18c

Registra	ant Name: <u>Clark &amp; Weinsto</u>	ck	
Client !	Name: PhRMA		•
Item	Description	Data	
	Lobbyist Name	Weber, Vin	
18b 18c	Covered Official Position New Lobbyist	No	

lient I	Name:	<u>PhRMA</u>			
engage	d in lobbyin	g on behalf o	f the client du	odes as necessary to uring the reporting p age(s) as needed.	reflect the general issue areas in which the registrant eriod. Using a separate page for each code, provide
15. G	ieneral issue	area code	MED	_ (one per page)	
	pecific Lobb ee attached				
I ! !	House(s) of ( Department Executive O House of Re Senate	of Health & ffice of the l	& Human Se: President	ncies contacted rvices	☐ Check if None
I 1 1 5	Department Executive O House of Re Senate	of Health & ffice of the l presentative	& Human Se President es	ncies contacted rvices  a lobbyist in this iss	
18.	Department Executive O House of Re Senate	of Health & ffice of the l presentative	& Human Se President es	rvices	
18.	Department Executive O House of Re Senate Name of eac	of Health & ffice of the l presentative h individual	& Human Se President es	rvices	sue area
18.	Department Executive O House of Re Senate Name of eac	of Health & ffice of the l presentative h individual	& Human Se President es	rvices	sue area
18.	Department Executive O House of Re Senate  Name of eac Name	of Health & ffice of the l presentative h individual	& Human Se President es	rvices	sue area
18.	Department Executive O House of Re Senate  Name of eac Name  Bieron, Bri Bonham, K	of Health & ffice of the l presentative h individual	k Human Ser President es who acted as	rvices	sue area
18.	Department Executive O House of Re Senate  Name of eac Name  Bieron, Bri Bonham, K	of Health & ffice of the l presentative h individual an ent	k Human Ser President es who acted as	rvices	sue area
18.	Department Executive O House of Re Senate  Name of eac Name  Bieron, Bri Bonham, K Fazio, Vic Glover We	of Health & ffice of the l presentative h individual an ent	k Human Ser President es who acted as	rvices	sue area  Covered Official Position (if applicable)

Date 8/6/04

Signature		Duit	_
Printed Name and Title	Vin Weber - Partner		F

Registrant Name: Clark & Weinstock

Client Name: PhRMA

Item	Description	Data
16	Lobbying Issues	H.R. 2673, Agriculture, Rural Development, Food & Drug Administration and Related Agencies Appropriations Act, 2004, sections related to FDA funding S. 51, Generic Pharmaceutical Access and Choice for Consumers Act of 2003; sections relating to substitution of generic drugs for innovator products. H.1, Medicare Prescription Drug and Modernization Act of 2003 & S. 1, Prescription Drug and Medicare Improvement Act of 2003, all sections relating new prescription drug benefits, drug access and reimportation. H.R. 2427, Pharmaceutical Market Access Act of 2003, relating to reimportatic S. 1992 Defense of Medicare and Real Prescription Drug Benefit Act Medicare Enhancements for Needed Drugs Act of 2004 Implementaion of Medicare lawP.L. 108-173; all sections related to prescripti drugs

18a	Lobbyist Name	Mathews, Jim
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No

Regis	strant Name:	Clark & Weinstock	
Clien	nt Name:	PhRMA	
enga	ged in lobbying	IVITY. Select as many codes as necessary to gon behalf of the client during the reporting pested. Attach additional page(s) as needed.	o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
15.	General issue	area code MMM (one per page)	
16.	Specific Lobb see attached		
17.		ongress and Federal agencies contacted of Health & Human Services presentatives	☐ Check if None
18.	Name of each	individual who acted as a lobbyist in this iss	sue area
	Name		Covered Official Position (if applicable)
	Bieron, Bria	n	
	Bonham, Ke	ent	
	Fazio, Vic		
	Glover Weis	s, Juleanna	
	Godes, Niles		Chief of Staff to Sen. Byron Dorgan (D-ND)
	Kutler, Ed		
	Lehman, Di	rksen	Special Asst. for Leg. Affairs for the President
19.	Interest of ea	ch foreign entity in the specific issues listed o	on line 16 above 🔀 Check if None

Signature		Date	
Printed Name and Title	Vin Weber - Partner		F

Registrant Name: Clark & Weinstock

Client Name:

**PhRMA** 

Item	Description	Data
16	Lobbying Issues	H.R. 2673, Agriculture, Rural Development, Food & Drug Administration and Related Agencies Appropriations Act, 2004, sections related to FDA funding S. 51, Generic Pharmaceutical Access and Choice for Consumers Act of 2003; sections relating to substitution of generic drugs for innovator products. H.1, Medicare Prescription Drug and Modernization Act of 2003 & S. 1, Prescription Drug and Medicare Improvement Act of 2003, all sections relating new prescription drug benefits, drug access and reimportation. H.R. 2427, Pharmaceutical Market Access Act of 2003, relating to reimportation S. 1992 Defense of Medicare and Real Prescription Drug Benefit Act Medicare Enhancements for Needed Drugs Act of 2004 Implementaion of Medicare lawP.L. 108-173; all sections related to prescript drugs

18a	Lobbyist Name	Mathews, Jim
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Morrison, Timothy
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Stuart, Sandi
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Weber, Vin
18b	Covered Official Position	
18c	New Lobbyist	No
TOF	Tien Mooding	

Kegist	rant Name:	Clark & Weinstock	
Client	Name:	<u>PhRMA</u>	
engage	ed in lobbyin	TVITY. Select as many codes as necessary to g on behalf of the client during the reporting pasted. Attach additional page(s) as needed.	o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
	General issue		
]	Specific Lobb Doha/Cancu Austrialia Fi		
	House of Re	Congress and Federal agencies contacted presentatives S. Trade Representative	☐ Check if None
18.	Name of eac	ch individual who acted as a lobbyist in this is	sue area
	Name		Covered Official Position (if applicable)
	Bieron, Bri	an	
_	Bonham, K	Cent	
	Fazio, Vic		
	Glover We	iss, Juleanna	
	Godes, Nile	es	Chief of Staff to Sen. Byron Dorgan (D-ND)
	Kutler, Ed		
			Special Asst. for Leg. Affairs for the President

Signature		 Date	V-T
Printed Name and Title	Vin Weber - Partner		]

Registrant Name: Clark & Weinstock

Client Name:

**PhRMA** 

Item	Description	Data
18a	Lobbyist Name	Mathews, Jim
18b 18c	Covered Official Position New Lobbyist	No
18a	Lobbyist Name	Morrison, Timothy
18b 18c	Covered Official Position New Lobbyist	No
18a	Lobbyist Name	Stach, Deirdre
18b 18c		No
18a	Lobbyist Name	Stuart, Sandi
18b 18c	1	No
18a	Lobbyist Name	Weber, Vin
18b 18c	Covered Official Position New Lobbyist	No

lient Name: PhRMA			
nformation Update Pag	ge - Complete ONLY where	e registration information has cha	inged.
20. Client new address			
21. Client new principal place of busi	iness (if different from line 20)		
City	State/Zip (or Country)		
22. New general description of client	's business or activities		
LOBBYIST UPDATE  23. Name of each previously r Bieron, Brian	reported individual who is no lo	onger expected to act as a lobbyist f	or the client
ISSUE UPDATE 24. General lobbying issues p AFFILIATED ORGANIZ	ZATIONS	ger pertain	
25. Add the following affiliat  Name	ed organization(s)	Address	Principal Place of Bo (city and state or co
26. Name of each previously	reported organization that is <b>n</b>	o longer affiliated with the registran	nt or client
FOREIGN ENTITIES 27. Add the following foreig	n entities		
Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities
		o longer owns, or controls, or is affi	12 / 1 / 14 / 1 / 14 / 14

M / W - -Filing #7240cbd7-ef4e-4ed3-a41d-243341b77eef - Page 21 of 22

Date 8/6/04

Signature		Date	-
Printed Name and Title	Vin Weber - Partner		F